GLP1 agonist weight loss medications Wegovy and Ozempic have become popular medications for overweight and obesity and are also increasingly being used in psychiatry to target symptoms of depression and anxiety. But are Wegovy and Ozempic safe to use in psychiatry? University of Toronto psychiatrist and researcher Dr. Rodrigo Mansur discusses the research supporting the use of GLP1 agonist weight loss drugs and explores his clinical considerations when discussing these medications with patients. Could they be a new treatment for psychiatric disorders? That remains to be seen as we consider the potential adverse effects. But it seems clear these drugs are becoming more popular, so the more we know about them, the better!
Expert featured in this episode:
Rodrigo Mansur MD PhD
https://psychiatry.utoronto.ca/faculty/rodrigo-mansur
Dr. Mansur's publication mentioned in this video:
Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study
https://pubmed.ncbi.nlm.nih.gov/27721184/
About us:
Metabolic Mind™ is a nonprofit initiative incubated by Baszucki Group. Our mission is to provide education and resources in the emerging field of metabolic psychiatry, including ketogenic interventions for mental disorders.
Our channel is for informational purposes only. We are not providing individual or group medical or healthcare advice nor establishing a provider-patient relationship. Many of the interventions we discuss can have dramatic or potentially dangerous effects if done without proper supervision. Consult your healthcare provider before changing your lifestyle or medications.
#MetabolicMind
#KetoForMentalHealth
#MetabolicPsychiatry
#BipolarTreatment
#KetogenicMetabolicTherapy
#NutritionalKetosis#MentalIllness#Bipolar#GLP1#Ozempic#Wegovy#Weightloss
